by Eclosion Team | Mar 28, 2017 | Uncategorized
Geneva (Switzerland), March 28, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), today provided access to research on...
by Eclosion Team | Mar 21, 2017 | Uncategorized
Lyon, France – 21 March 2017 – NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors. NETRIS Pharma, a pioneer in the development of dependence receptor targeted cancer medicines, announced today the start of...
by Eclosion Team | Feb 28, 2017 | Uncategorized
February 28, 2017 Genticel’s General Meeting approves the strategic Combination with GenKyoTex SA Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies (the “Company”), and GenKyoTex SA, a...
by Eclosion Team | Feb 7, 2017 | Uncategorized
Geneva (Switzerland), 7 February 2017 : (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), announced today the signing of a Cooperative...
by Eclosion Team | Dec 22, 2016 | Uncategorized
Toulouse and Geneva, December 22, 2016 Genticel and Genkyotex Announce Intention to Enter into Strategic Combination. Genkyotex is a pioneer in discovery and development of NOX therapeutics. Transaction would create a European group with a pipeline of first-in-class...
by Eclosion Team | Dec 7, 2016 | Uncategorized
The ANGEL-MS extension study will offer the 260 patients enrolled in the on-going Phase IIb CHANGE-MS study the opportunity to continue their treatment for an additional two years and will provide additional efficacy and tolerance data. Geneuro, Switzerland and...